You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

VEGF

Showing 26 - 50 of 3,749
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Clear Cell Kidney Cancer, Kidney Cancer, Kidney Cancer With PBRM1/BAP1/VHL/SETD2 Mutations Trial (Axitinib 5 MG)

Available
  • Clear Cell Kidney Cancer
  • +2 more
  • Axitinib 5 MG
  • (no location specified)
Jul 3, 2023

Ovarian Clear Cell Adenocarcinoma, Platinum-Sensitive Ovarian Carcinoma, Recurrent Endometrial Serous Adenocarcinoma Trial in

Not yet recruiting
  • Ovarian Clear Cell Adenocarcinoma
  • +14 more
  • Anti-CD40 Agonist Monoclonal Antibody CDX-1140
  • +4 more
  • Buffalo, New York
  • +1 more
Dec 16, 2022

Ovarian Cancer Trial in Houston (Paclitaxel, Bevacizumab, Lurbinectedin)

Not yet recruiting
  • Ovarian Cancer
  • Houston, Texas
    M D Anderson Cancer Center
Nov 23, 2022

s in Wet AMD in Active Smokers

Completed
  • Wet Age-related Macular Degeneration
  • Medical Data extraction
  • Brussels, Belgium
    CHU Brugmann
Mar 7, 2022

Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Tumor in the Brain, Stage IV Lung Non-Small Cell Cancer AJCC v7

Active, not recruiting
  • Metastatic Lung Non-Small Cell Carcinoma
  • +2 more
  • Bevacizumab
  • +2 more
  • Los Angeles, California
  • +17 more
Jan 27, 2023

Hepatocellular Carcinoma Trial (PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab, TACE)

Recruiting
  • Hepatocellular Carcinoma
  • PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab
  • TACE
  • Nanjing, China
  • +1 more
Dec 28, 2022

Hepatocellular Carcinoma Trial (PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab, TACE)

Recruiting
  • Hepatocellular Carcinoma
  • PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab
  • TACE
  • Nanjing, China
  • +1 more
Dec 28, 2022

Metastatic Colorectal Carcinoma, Metastatic Malignant Tumor in the Liver, Stage IV Colorectal Cancer AJCC v8 Trial (biological,

Not yet recruiting
  • Metastatic Colorectal Carcinoma
  • +3 more
  • Bevacizumab
  • +11 more
  • (no location specified)
May 9, 2023

Liver Cancer Trial in Houston (Bevacizumab, Atezolizumab, Sofosbuvir)

Not yet recruiting
  • Liver Cancer
  • Houston, Texas
    M D Anderson Cancer Center
Feb 9, 2023

SCLC Trial (PM8002, Platinum, Atezolizumab)

Not yet recruiting
  • SCLC
  • (no location specified)
May 4, 2023

Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IIIC Lung Cancer AJCC v8 Trial in

Recruiting
  • Metastatic Lung Non-Small Cell Carcinoma
  • +5 more
  • Bevacizumab
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Jul 13, 2022

Recovery in Post-stroke Rehabilitation

Completed
  • Ischemic Stroke
    • Lodz, Poland
      Medical University of Lodz
    Feb 20, 2023

    Locally Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell

    Recruiting
    • Locally Advanced Lung Non-Small Cell Carcinoma
    • +9 more
    • Duarte, California
    • +4 more
    Aug 17, 2022

    HIF-1 Alpha, VEGF and MMP-8 Levels in PICF of Smokers Versus Non

    Completed
    • Peri-Implantitis
      • Cairo, Egypt
        Faculty of oral and dental medicine,FUE, Cairo,Egypt
      Apr 13, 2022

      Glioma, Recurrent Glioma Trial in Shanghai (Hypofractionated Stereotactic Radiotherapy, Bevacizumab)

      Active, not recruiting
      • Glioma
      • Recurrent Glioma
      • Shanghai, Shanghai, China
        CyberKnife Center, Department of Neurosurgery, Huashan Hospital
      Nov 3, 2022

      Liver Cancer Trial in Houston (Bevacizumab, Erlotinib)

      Completed
      Has Results
      • Liver Cancer
      • Houston, Texas
        University of Texas MD Anderson Cancer Center
      Nov 3, 2022

      Clinical Stage III Cutaneous Melanoma AJCC v8, Stage IV Melanoma, Unresectable Stage III Cutaneous Melanoma Trial in Boston

      Recruiting
      • Clinical Stage III Cutaneous Melanoma AJCC v8
      • +3 more
      • Boston, Massachusetts
      • +2 more
      Sep 17, 2022

      Advanced Cancer Trial in Houston (Temsirolimus, Bevacizumab, Paclitaxel)

      Active, not recruiting
      • Advanced Cancer
      • Houston, Texas
        University of Texas MD Anderson Cancer Center
      Oct 11, 2022

      Cervical Adenocarcinoma, Cervical Adenosarcoma, Cervical Adenosquamous Carcinoma Trial in United States (biological, other,

      Recruiting
      • Cervical Adenocarcinoma
      • +47 more
      • Bevacizumab
      • +3 more
      • Phoenix, Arizona
      • +3 more
      Dec 5, 2022

      Giant Cell Glioblastoma, Glioblastoma, Gliosarcoma Trial in Los Angeles, San Diego (biological, drug, other, genetic)

      Active, not recruiting
      • Giant Cell Glioblastoma
      • +2 more
      • bevacizumab
      • +5 more
      • Los Angeles, California
      • +2 more
      Feb 10, 2022

      Aflibercept in Routine Clinical Practice in Diabetic Macular

      Completed
      • Macular Edema
      • Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)
      • Anti-VEGF therapies including: Eylea Aflibercept, VEGF Trap-Eye, BAY86-5321) and Ophthalmologicals / Antineovascularisation agents (S01LA05)
      • Multiple Locations, United Kingdom
        (unnamed)
      Nov 1, 2021

      Metastatic Colon Adenocarcinoma, Metastatic Colorectal Adenocarcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma

      Not yet recruiting
      • Metastatic Colon Adenocarcinoma
      • +6 more
      • Balstilimab
      • +10 more
      • Duarte, California
        City of Hope Medical Center
      Nov 17, 2022

      Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for

      Recruiting
      • Hepatocellular Carcinoma Non-resectable
      • HAIC
      • +8 more
      • Quanzhou, Fujian, China
      • +1 more
      Jan 26, 2023

      Peritoneal Malignant Mesothelioma Trial in United States (biological, drug, procedure)

      Recruiting
      • Peritoneal Malignant Mesothelioma
      • Atezolizumab
      • +8 more
      • Phoenix, Arizona
      • +25 more
      Feb 2, 2023

      Solid Tumor, Adult Trial in Guangzhou (AK112)

      Active, not recruiting
      • Solid Tumor, Adult
      • Guangzhou, Guangdong, China
        Sun Yat-sen University Cancer Center
      Oct 8, 2022